fda glp-1 compounding crackdown news today New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Crackdown Puts Pressure on

Several state Medicaid programs cover obesity treatment (California, Pennsylvania, plus ~12 others)

The two manufacturers of approved GLP-1s, Lilly and Novo Nordisk, have set up online platforms to bypass both compounding and traditional pharmacies, and Lilly has partnered with three telehealth services to provide access to obesity-trained doctors and registered dietitians

[cited 2025 Mar 20]

That's why producers may run into formulation hurdles when adding these functional ingredients

(1998) found that in cultured lamb adenohypophysial cells, the combination of 10 nM GHRH plus 1 M GHRP-6 was not significantly different from GHRH alone

For someone starting at 180 pounds, that may look more like 18 to 27 pounds